TNF and clostridium difficile infection: Similarly, a meta-analysis of 30 studies by Chen et al. showed a higher CDI risk in UC patients receiving vedolizumab compared to those with CD, which implicates that Vedolizumab could potentially be offering an advantage over anti-TNF agents for UC regarding CDI risk, but not for CD [51].